Julia Martínez-Sole

Mrs. Julia Martínez-Sole


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2024 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
Eva Cabrera-BorregoEva Cabrera-Borrego
Eva Cabrera-Borrego
FBFrancisco José Bermúdez-Jiménez
Francisco José Bermúdez-Jiménez
AGAlessio Gasperetti
Alessio Gasperetti
HTHarikrishna Tandri
Harikrishna Tandri
PSPablo J. Sánchez-Millán
Pablo J. Sánchez-Millán
JJJuan Jiménez Jáimez
Juan Jiménez Jáimez
BACKGROUND: Among inherited cardiomyopathies involving the left ventricle, whether dilated or not, certain genotypes carry a well-established arrhythmic risk, notably manifested as sustained monomorphic ventricular tachycardia (SMVT). Nonetheless, the precise localization and electrophysiological profile of this substrate remain undisclosed across different genotypes. METHODS: Patients diagnosed with cardiomyopathy and left ventricle involvement due to high-risk genetic variants and SMVT treated by electrophysiological study were recruited from 18 European/US centers. Electrophysiological study, imaging, and outcomes data after ablation were assessed in relation to genotype. RESULTS: Seventy-one patients were included (49.6 Q1–Q3 [40–60] years, 76% men). They were divided into 4 groups according to the affected protein: desmosomal ( DSP , PKP2 , DSG2 , and DSC2 ), nuclear membrane ( LMNA and TMEM43 ), cytoskeleton ( FLNC and DES ), and sarcoplasmic reticulum ( PLN ). Desmosomal genes, TMEM43 , and PLN were associated with biventricular disease, while variants in LMNA and cytoskeleton genes had predominant left ventricle involvement ( P =0.001). The location of the clinical-SMVT substrate was significantly different based on genotype ( P =0.005). DSP and cytoskeleton genes presented SMVTs with right bundle branch block morphology, which origin was identified in the inferolateral segments of the left ventricle. The other desmosomal genes ( PKP2 and DSG2 ), along with TMEM43 , showed SMVTs with left bundle branch block morphology and predominantly right ventricular substrate. In contrast, LMNA substrate was mainly observed in the interventricular septum. During a median of 26 Q1–Q3 (10.6–65) months, 27% of patients experienced recurrences of clinical SMVT with differences between genotypes (log-rank 0.016). Nuclear membrane genes demonstrated the highest recurrence rate compared with desmosomal genes (hazard ratio, 4.56 [95% CI, 1.5–13.8]). CONCLUSIONS: The anatomic substrate of SMVTs shows a strong correlation with the underlying genotype, electrocardiographic morphology, and recurrence rate. Particularly, patients with nuclear membrane gene variants have a significantly higher recurrence rate compared with those with desmosomal gene variants.

18 March 2025 in Life
Verified
Journal Article
Open access
PDF file
RVRaquel López Vilella
Raquel López Vilella
FGFrancisco Gonzalez-Vilchez
Francisco Gonzalez-Vilchez
BCBorja Guerrero Cervera
Borja Guerrero Cervera
VDVíctor Donoso-Trenado
Víctor Donoso-Trenado
ZCZoser Saura Carretero
Zoser Saura Carretero
Luís Almenar-BonetLuís Almenar-Bonet
Luís Almenar-Bonet
This study aims to analyze the factors associated with the lack of carbohydrate antigen 125 (CA-125) elevation in cases of acute heart failure (HF) decompensation. This retrospective study was conducted on 3167 consecutive patients admitted for acute HF in the cardiology department of a referral hospital (June 2019 to June 2024). Admissions from outpatient clinics (n: 1018) and transfers from other hospitals (n: 752) were excluded. The variables of interest included clinical, echocardiographic, therapeutic, and analytical factors. Low CA-125 levels were defined as values ≤ 50 U/mL. A total of 1397 patients were included, of whom 515 had normal CA-125 levels and 882 had elevated levels. Clinically, independent predictors of low CA-125 were sinus rhythm on electrocardiogram (OR: 1.42, 95% CI: 1.12–1.64; p: 0.003) and sleep apnea–hyponpnea syndrome (OR: 1.76, 95% CI: 1.15–2.70; p: 0.009). Echocardiographically, inferior vena cava collapse greater than 50% with inspiration was associated with low CA-125 (OR: 1.78, 95% CI: 1.19–2.69; p = 0.005), as well as with non-severe right ventricular dysfunction. (OR: 2.42; IC95%: 1.39–4.20; p: 0.002). Analytically, elevated NT-proBNP levels were associated with elevated CA-125 levels (OR: 0.99; IC95%: 0.99–0.99; p: 0.006). Survival was higher in the group with CA-125 ≤ 50 U/mL (p: 0.019). Conversely, as CA-125 values increased, mortality also rose. In conclusion, the absence of CA-125 elevation in patients admitted for acute HF is associated with sinus rhythm, sleep apnea–hyponpnea syndrome, low NT-proBNP levels, and inferior vena cava collapse greater than 50% with inspiration.

9 July 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
RLRaquel Lopez-Vilella
Raquel Lopez-Vilella
BCBorja Guerrero Cervera
Borja Guerrero Cervera
VDVíctor Donoso-Trenado
Víctor Donoso-Trenado
JMJulia Martínez-Sole
Julia Martínez-Sole
SMSara Huélamo Montoro
Sara Huélamo Montoro
Luís Almenar-BonetLuís Almenar-Bonet
Luís Almenar-Bonet
Background/Objectives: Patients diagnosed with decompensated congestive heart failure (HF) often have elevated CA-125 levels, attributed to systemic congestion. However, a subgroup of patients presents with normal CA-125 levels. The primary objective of this study was to characterize the clinical, analytical, and echocardiographic profiles of patients admitted for decompensated congestive HF according to their CA-125 levels. The secondary objective was to analyze mortality after discharge. Methods: We conducted a retrospective study of patients hospitalized for a decompensated congestive HF episode. Recruitment was consecutive over more than 4 years (December 2019–June 2024), with 3151 patients recruited. Scheduled admissions, transfers from other hospitals, pulmonary congestion patterns, mixed patterns, and low output were the exclusion criteria. The final number of patients included was 166, all with an isolated systemic congestion pattern: CA-125 ≤ 50 U/mL: 38, and CA-125 > 50 U/mL: 128. Results: The comparative analysis between the groups showed that patients with CA-125 ≤ 50 U/mL were more often women (p < 0.05). They also had lower bilirubin and GOT/AST levels (p < 0.05). The percentage of patients with a preserved left ventricular ejection fraction (≥50%) was higher in the CA-125 ≤ 50 U/mL group (p < 0.05). The right ventricular (RV) size and inferior vena cava (IVC) were enlarged in both groups but with no significant differences (p < 0.05). However, the degree of RV dysfunction was greater in the CA-125 > 50 U/mL group, while the proportion of patients with inspiratory collapse of the IVC was higher in the CA-125 ≤ 50 U/mL group (p < 0.05). Survival curves differed from the first month and throughout the follow-up, with higher mortality in the CA-125 > 50 U/mL group. Thus, the probability of being alive at the end of the follow-up was over 50% in the CA-125 ≤ 50 U/mL group, while in the CA-125 > 50 U/mL group, it was around 25% (p < 0.05). Conclusions: The proportion of patients with decompensated congestive HF and systemic congestion who present with a low CA-125 level is close to 25%. These patients are mostly women with a preserved ejection fraction and inspiratory collapse of the IVC of >50%. Moreover, they have a higher survival rate, so a low CA-125 could help identify a subgroup of patients with a better prognosis.

3 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
BCBorja Guerrero Cervera
Borja Guerrero Cervera
RLRaquel Lopez-Vilella
Raquel Lopez-Vilella
RCRicardo Gimeno Costa
Ricardo Gimeno Costa
FEFrancisca Pérez Esteban
Francisca Pérez Esteban
MGManuel Pérez Guillén
Manuel Pérez Guillén
Luís Almenar-BonetLuís Almenar-Bonet
Luís Almenar-Bonet
Background/Objectives: Fulminant myocarditis (FM) is an uncommon but potentially reversible form of myocardial inflammation that can rapidly progress to cardiogenic shock (CS). In patients who are refractory to conventional treatment, venoarterial extracorporeal membrane oxygenation (VA-ECMO) represents an effective life support strategy. However, the factors that determine functional recovery remain uncertain. The primary objective of this study was to characterize patients who recover ventricular function. Secondary objectives included analyzing VA-ECMO-related complications and overall patient survival. Methods: This was a retrospective, single-center, observational study including all consecutive patients diagnosed with FM between 2008 and 2025 who were supported with VA-ECMO (n = 22). Clinical, biochemical, echocardiographic, and imaging variables were collected. Patients were classified based on their outcomes as either recovery or death/transplantation. Differential factors potentially affecting myocardial recovery, survival, and complications were analyzed. Results: The mean age was 49.7 ± 11 years, with 36% being male. Severe cardiogenic shock was the most common initial presentation (86%), and the average time from symptom onset to hospital admission was 5.7 days. Regarding mechanical support, the non-recovery group required longer ECMO support (328 ± 225 h vs. 188 ± 103 h; p = 0.03). The presence of fibrosis on cardiac magnetic resonance imaging (MRI) was associated with a lower probability of recovery (100% vs. 44.4%; p = 0.03). Renal failure and vascular complications were more frequent in the non-recovery group, with a significantly higher rate of surgical reintervention (50% vs. 10%; p = 0.04). Echocardiography performed before discharge (recovery group) vs. before death/transplant (non-recovery group) showed significant differences in left ventricular ejection fraction (51.1% vs. 29.5%; p = 0.04), along with better levels of creatinine, N-terminal pro-B-type natriuretic peptide (NT-proBNP), leukocytes, and C-reactive protein (CRP) in the recovery group. In-hospital survival for the entire cohort was 63.6%, significantly higher in the recovery group (100% vs. 33.3%; p < 0.01). One-year survival was 59%, which was also greater among those who recovered (90% vs. 33.3%; p = 0.02). Conclusions: FM is associated with an acceptable in-hospital survival rate. The presence of myocardial fibrosis on MRI and longer ECMO support duration were observed to be associated with a lower likelihood of cardiac recovery. Patients who recovered showed better ventricular function at discharge, as well as reduced systemic inflammation and renal dysfunction. These findings highlight the importance of early identification of predictors of myocardial recovery to optimize management and therapeutic decision making in this high-risk population.

8 May 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
VDVíctor Donoso-Trenado
Víctor Donoso-Trenado
OGOscar Otero Garcia
Oscar Otero Garcia
RLRaquel Lopez-Vilella
Raquel Lopez-Vilella
PLPablo de la Fuente López
Pablo de la Fuente López
JMJulia Martínez-Sole
Julia Martínez-Sole
Luís Almenar-BonetLuís Almenar-Bonet
Luís Almenar-Bonet
Background/Objectives: Patients hospitalized for de novo heart failure with reduced ejection fraction (HFrEF) may experience improvement in left ventricular function, a phenomenon associated with improved morbidity and mortality outcomes. However, the factors influencing this improvement remain unclear. This study aimed to investigate the association between clinical and therapeutic factors and short-term improvement or recovery of left ventricular ejection fraction (LVEF) in patients hospitalized with newly diagnosed heart failure with reduced ejection fraction (HFrEF). Methods: This was a prospective observational study conducted in two referral centers in Spain. All patients admitted with de novo HFrEF between March 2021 and December 2023 were included. Improved myocardial function (HFimpEF) was defined as an initial LVEF ≤ 40% and a follow-up echocardiogram showing LVEF > 40%, with an increase of ≥10 points from baseline. Results: In total, 157 patients (63.3%) met the criteria for HFimpEF. Among the various etiologies of heart failure, significant differences were found between groups for tachycardiomyopathy (HFimpEF: 29.3% vs. non-HFimpEF: 13.1%, p = 0.006), valvular (HFimpEF: 7.6% vs. non-HFimpEF: 1.1%, p = 0.05), and ischemic (HFimpEF: 17.2% vs. non-HFimpEF: 43.9%, p < 0.0001) etiologies. Multivariate analysis showed that non-ischemic etiologies significantly favored myocardial improvement compared to ischemic cardiomyopathy. NT-proBNP values were consistently higher in the non-HFimpEF group at all time points measured with statistically significant differences, except at admission. Event-free survival curves (hospitalization for HF, worsening HF, and all-cause mortality) diverged early, showing statistically significant differences between groups. Conclusions: Overall, 63% of patients hospitalized for de novo HFrEF achieved myocardial improvement within an average of 3–4 months, with improvement favored by valvular and tachycardiomyopathy etiologies. This improvement has a significant prognostic impact.

17 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
RLRaquel Lopez-Vilella
Raquel Lopez-Vilella
BCBorja Guerrero Cervera
Borja Guerrero Cervera
VDVíctor Donoso-Trenado
Víctor Donoso-Trenado
JMJulia Martínez-Sole
Julia Martínez-Sole
SMSara Huélamo Montoro
Sara Huélamo Montoro
Luís Almenar-BonetLuís Almenar-Bonet
Luís Almenar-Bonet
Aims: Patients diagnosed with decompensated congestive heart failure (HF) often have elevated CA-125 levels, attributed to systemic congestion. However, a subgroup presents with normal CA-125 levels. The primary objective of this study was to characterize the clinical, analytical, and echocardiographic profile of patients admitted for decompensated congestive HF according to CA-125 levels. The secondary objective was to analyze mortality after discharge. Methods: A retrospective study of patients hospitalized for a decompensated congestive HF episode. Recruitment was consecutive over more than 4 years (December 2019 – June 2024), with 3,151 patients. Scheduled admissions, transfers from other hospitals, pulmonary congestion patterns, mixed patterns, and low output were excluded. The final number of patients included was 166, all with an isolated systemic congestion pattern: CA-125 ≤50 U/mL: 38 and CA-125 >50 U/mL: 128. The diagnosis of decompensated congestive HF was defined as the presence of fluid retention manifested by significant weight gain, reduced diuresis, and severe edema, without evidence of orthopnea or signs of low cardiac output. Pulmonary congestion was required to be absent. In cases of doubt, patients were evaluated by a multidisciplinary team. Results: The comparative analysis between the groups showed that patients with CA-125 ≤50 U/mL were more often women (p50 U/mL group, it was around 25% (p< 0.05). Conclusions: The proportion of patients with decompensated congestive HF and systemic congestion who present with a low CA-125 level is close to 25%. These patients are mostly women with preserved ejection fraction and inspiratory collapse of the IVC >50%. Moreover, they have a higher survival rate, so a low CA-125 could help identify a subgroup of patients with a better prognosis.